Jason Bednar
Stock Analyst at Piper Sandler
(2.21)
# 2,764
Out of 5,157 analysts
202
Total ratings
40%
Success rate
-3.49%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRTS Alpha Tau Medical | Downgrades: Neutral | $5 | $6.84 | -26.90% | 6 | Mar 4, 2026 | |
| ICUI ICU Medical | Maintains: Overweight | $172 → $178 | $132.41 | +34.43% | 4 | Feb 20, 2026 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $113 → $106 | $69.71 | +52.06% | 15 | Feb 18, 2026 | |
| BDX Becton, Dickinson and Company | Reiterates: Neutral | $205 → $170 | $163.88 | +3.73% | 13 | Feb 10, 2026 | |
| NVST Envista Holdings | Reiterates: Neutral | $21 → $25 | $26.00 | -3.85% | 15 | Feb 6, 2026 | |
| ALGN Align Technology | Maintains: Overweight | $200 → $220 | $169.43 | +29.85% | 33 | Feb 5, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Overweight | $91 → $94 | $72.73 | +29.25% | 2 | Jan 30, 2026 | |
| MDLN Medline | Initiates: Overweight | $50 | $42.88 | +16.60% | 1 | Jan 12, 2026 | |
| SHC Sotera Health Company | Upgrades: Overweight | $17 → $24 | $14.06 | +70.70% | 4 | Jan 9, 2026 | |
| COO The Cooper Companies | Reiterates: Overweight | $83 → $94 | $74.41 | +26.33% | 15 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $94 → $98 | $67.60 | +44.97% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $4 | $4.53 | -11.70% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $210 | $175.49 | +19.66% | 16 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $2.5 | $1.79 | +40.06% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $12.75 | +166.67% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $12.68 | +26.18% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $76.29 | +0.93% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $4.39 | +2.51% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $222.08 | +19.33% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.34 | +79.64% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $0.82 | +2,325.71% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $485.85 | -23.43% | 4 | Jan 3, 2024 |
Alpha Tau Medical
Mar 4, 2026
Downgrades: Neutral
Price Target: $5
Current: $6.84
Upside: -26.90%
ICU Medical
Feb 20, 2026
Maintains: Overweight
Price Target: $172 → $178
Current: $132.41
Upside: +34.43%
Merit Medical Systems
Feb 18, 2026
Maintains: Overweight
Price Target: $113 → $106
Current: $69.71
Upside: +52.06%
Becton, Dickinson and Company
Feb 10, 2026
Reiterates: Neutral
Price Target: $205 → $170
Current: $163.88
Upside: +3.73%
Envista Holdings
Feb 6, 2026
Reiterates: Neutral
Price Target: $21 → $25
Current: $26.00
Upside: -3.85%
Align Technology
Feb 5, 2026
Maintains: Overweight
Price Target: $200 → $220
Current: $169.43
Upside: +29.85%
GE HealthCare Technologies
Jan 30, 2026
Maintains: Overweight
Price Target: $91 → $94
Current: $72.73
Upside: +29.25%
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $50
Current: $42.88
Upside: +16.60%
Sotera Health Company
Jan 9, 2026
Upgrades: Overweight
Price Target: $17 → $24
Current: $14.06
Upside: +70.70%
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $74.41
Upside: +26.33%
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $67.60
Upside: +44.97%
Aug 7, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $4.53
Upside: -11.70%
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $175.49
Upside: +19.66%
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.79
Upside: +40.06%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $12.75
Upside: +166.67%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $12.68
Upside: +26.18%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $76.29
Upside: +0.93%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $4.39
Upside: +2.51%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $222.08
Upside: +19.33%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.34
Upside: +79.64%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $0.82
Upside: +2,325.71%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $485.85
Upside: -23.43%